SGLT2i in CKD with high albuminuria: an observational real-world study

被引：0
|
作者：
Svensson, Maria K. [1 ]
Bodegard, Johan [2 ]
Thuresson, Marcus [3 ]
Ambery, Philip [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] AstraZeneca, Gothenburg, Sweden
[3] Statisticon AB, Uppsala, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.147
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
2638
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Changes in SGLT2i and GLP-1RA Real-World Initiator Profiles following Cardiovascular Outcome Trials-A Danish Nationwide Population-Based Study
    Knudsen, Jakob S.
    Baggesen, Lisbeth Munksgard
    Lajer, Maria
    Nurkanovic, Larisa
    Ustyugova, Anastasia V.
    Sorensen, Henrik T.
    Thomsen, Reimar W.
    DIABETES, 2019, 68
  • [42] Real-life introduction of SGLT2i during an hospitalization for heart failure
    Brisse, A.
    Huttin, O.
    Zannad, N.
    Girerd, N. Nicolas
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 304 - 304
  • [43] SGLT2i in heart failure with reduced ejection fraction: benefits in real life?
    Sanchez Gonzalez, V. Virtudes
    Flano-Lombardo, R.
    Esteve-Ruiz, I.
    Cortez, G.
    Aranda-Dios, A.
    Duran-Torralba, C.
    Rangel-Sousa, D.
    Sobrino-Marquez, J. M.
    Grande-Trillo, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 72 - 73
  • [44] Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
    Ito, Yuichiro
    Van Schyndle, James
    Nishimura, Takuya
    Sugitani, Toshifumi
    Kimura, Tomomi
    DIABETES THERAPY, 2019, 10 (02) : 549 - 562
  • [45] Real-World Analysis of SGLT2 Inhibitors to Prevent Cardiovascular and Kidney Outcomes in Patients with CKD: A Population-Based Cohort Study
    Toro, Luis
    Valderrama, Josefa
    Polanco, Diego
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [46] A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
    Liu, Allen Yan Lun
    Low, Serena
    Yeoh, Ester
    Lim, Eng Kuang
    Renaud, Claude Jeffrey
    Teoh, Selene Tse Yen
    Tan, Grace Feng Ling
    Chai, Chung Cheen
    Liu, Bo
    Subramaniam, Tavintharan
    Sum, Chee Fang
    Lim, Su Chi
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1403 - 1414
  • [47] Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
    Yuichiro Ito
    James Van Schyndle
    Takuya Nishimura
    Toshifumi Sugitani
    Tomomi Kimura
    Diabetes Therapy, 2019, 10 : 549 - 562
  • [48] Risk of diabetic microvascular complications, heart failure, hospitalisation and all-cause mortality with SGLT2i and GLP1-ra in type 2 diabetes: a real-world data study
    Eleftheriadou, A.
    Riley, D.
    Austin, P.
    Hernandez, G.
    Alam, U.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S74 - S74
  • [49] DETERMINANTS OF EFFECTS OF SGLT2I ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNEY TRIAL
    Tang, Francesca
    NEPHROLOGY, 2023, 28 : 29 - 30
  • [50] SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series
    Zampieri, Mattia
    Argiro, Alessia
    Allinovi, Marco
    Perfetto, Federico
    Cappelli, Francesco
    INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (04) : 1243 - 1245
12345